Acceleration Biopharmaceuticals is categorized under Commercial Biotechnical Research in Woburn, MA and active since 2003.
Acceleration Biopharmaceuticals was established in 2003, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Nancy Livy at the company’s single location by writing to 3e Gill St, Woburn, Massachusetts MA 01801 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Acceleration Biopharmaceuticals |
| Contact Person: | Nancy Livy |
| Address: | 3e Gill St, Woburn, Massachusetts 01801 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2003 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Acceleration Biopharmaceuticals was started in 2003 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Nancy Livy for inquiries that concern Acceleration Biopharmaceuticals by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Acceleration Biopharmaceuticals can be found at the coordinates 42.510369,-71.147275 as well as the street address 3e Gill St in Woburn, Massachusetts 01801.
For its online presence, you may visit Acceleration Biopharmaceuticals’s website at and engage with its social media outlets through on Twitter and on Facebook.